Figure 7 Treatment algorithm for perianal fistulizing disease

Slides:

Advertisements

Similar presentations

Surgical Management Inflammatory Bowel Disease Ernesto R. Drelichman, MD, FACS St. John Health Systems.

Advertisements

Date of download: 6/9/2016 From: Diagnosis and Treatment of Perianal Fistulas in Crohn Disease Ann Intern Med. 2001;135(10): doi: /

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Exosome composition

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 1 Patients cured of HCV infection

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 7 Management algorithm for patients with ACLF

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 4 Simple perianal fistula

Figure 5 Two approaches to therapeutic genome editing

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 The T-cell cytokine tree in IBD

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

QP Forum 12 April 2018 Trinity College, Dublin Ireland

Figure 3 Algorithm from working group describing

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Complex perianal fistula

Endoscopic ultrasound for perianal Crohn's disease: Disease and fistula characteristics, and impact on therapy Adi Lahat, Yehudit Assulin, Marc Beer-Gabel,

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Linda A. Feagins, Stefan D. Holubar, Sunanda V. Kane, Stuart J

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

A 31-Year-Old Patient With Colitis and Perianal Disease

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Examples of reflux episodes on pH and pH-impedance monitoring

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 5 Hepatic regeneration in ACLF

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

AGA technical review on perianal Crohn’s disease

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

with broad-spectrum antibiotics

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 2 New therapeutic approaches in IBD with their specific targets

Conventional Medical Management of Inflammatory Bowel Disease

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Distribution of markers of active HBV infection

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Management of Perianal Crohn’s Disease

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 7 Treatment algorithm for perianal fistulizing disease Figure 7 | Treatment algorithm for perianal fistulizing disease. Anatomic characteristics of the fistulas, presence of abscesses and presence of proctitis are the main determinants of the therapeutic strategy. For patients with complex fistulas and/or proctitis, a top-down approach is preferred. Timely assessment of response to medical therapy is essential to initiate alternative therapies or surgery. IMS, immunosuppressant; LIFT, ligation of the intersphincteric fistula tract; MSCs, mesenchymal stem cells. Panés, J. & Rimola, J. (2017) Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.104